Submitted by mphilemon@resea... on Fri, 01/07/2011 - 12:11
Slides from presentations at ASH 2010 and transcribed comments from a recent interview
with Rafael Fonseca, MD (12/22/10)
Niesvizky R et al. Phase 3b UPFRONT study: Safety and efficacy of weekly bortezomib maintenance therapy after bortezomib-based induction regimens in elderly, newly diagnosed multiple myeloma patients. Proc ASH 2010;Abstract 619.
Palumbo A et al. Bortezomib, melphalan, prednisone and thalidomide followed by maintenance with bortezomib and thalidomide (VMPT-VT) for initial treatment of elderly multiple myeloma patients: Updated follow-up and impact of prognostic factors. Proc ASH 2010;Abstract 620.
Dr Fonseca is Professor of Medicine at the Mayo Clinic Arizona and Deputy Director of the Mayo Clinic Cancer Center in Scottsdale, Arizona.
